Pharmaceutical Manufacturing in India

Pharmaceutical Manufacturing in India: Managing Changes in Raw Material Suppliers

Medical
October 27, 2026

What Is a Raw Material Supplier Change?

A raw material supplier change occurs when a pharmaceutical manufacturer proposes a change to the source or supply arrangement for a material used in production.

The change may involve an active pharmaceutical ingredient, an excipient or another material used during manufacturing.

Examples of Supplier Changes Include:

• Purchasing a material from a new manufacturer.
• Purchasing from a new distributor while retaining the same manufacturer.
• Changing the manufacturing site for an existing material.
• Adding an alternative source for supply continuity.
• Replacing a supplier that can no longer provide the material.
• Changing the route through which a material is stored or transported.
• Receiving a material produced using a changed process at an existing supplier.

Each change should be assessed according to its nature and potential effect. A new distributor and a new material manufacturer may present different risks and require different evidence.

Why Do Supplier Changes Need Careful Assessment?

Raw materials can influence product quality, manufacturing performance and supply continuity.

Two materials may meet the same general specification but behave differently during processing. For example, differences in particle size, moisture content or flow properties may affect blending, compression or dissolution.

A Supplier Change May Affect:

• Product quality attributes.
• Manufacturing consistency.
• Impurity profiles.
• Analytical testing requirements.
• Process performance.
• Stability.
• Regulatory commitments.
• Batch documentation.
• Supply continuity.
• Customer and quality agreements.

ICH Q10 describes change management as part of the pharmaceutical quality system and recommends evaluating changes using quality risk management. database.ich.org

Identify the Reason for the Proposed Change

Start by documenting why the supplier change is being considered.

A clear reason helps the team understand the urgency, available alternatives and activities needed before implementation.

Common Reasons Include:

• Supply interruption or shortage.
• Supplier discontinuation.
• Capacity limitations.
• Repeated quality concerns.
• A change in supplier ownership or manufacturing site.
• Commercial or procurement considerations.
• A need for an additional approved source.
• Changes to transport or distribution arrangements.

A commercial advantage should be considered alongside product quality, regulatory and supply-chain requirements.

If the change is urgent, document the reason for the urgency and apply the applicable change-control procedure.

Open a Formal Change-Control Record

A supplier change should be documented through the organisation’s quality system before the new source is introduced.

The change record provides a place to identify the proposal, assign responsibilities and track the evidence needed for approval.

The Change Record Should Include:

• Material name and internal code.
• Material function and grade.
• Existing approved manufacturer and supplier.
• Proposed manufacturer, site and supplier.
• Reason for the change.
• Products and manufacturing sites affected.
• Proposed implementation date.
• Initial quality and supply-chain risks.
• Required assessments and approvals.
• Responsible departments and target dates.

For active pharmaceutical ingredient manufacturing, ICH Q7 guidance states that a change in the source of critical raw materials should be managed through change control. FDA

Distinguish the Manufacturer From the Distributor

The company selling the material may not be the company that manufactures it.

A change in distributor may leave the manufacturing source unchanged, while a change in manufacturer can introduce a different process, facility or material profile.

Information to Confirm:

• Name and address of the actual manufacturer.
• Manufacturing site for the proposed material.
• Name and address of the distributor or agent.
• Storage locations along the supply chain.
• Transport arrangements.
• Repackaging or relabelling activities, if any.
• Traceability from the manufacturer to the receiving site.
• Parties responsible for handling quality concerns.

For critical materials used in API manufacturing, ICH Q7 states that the manufacturer’s name and address should be known when the supplier is not the manufacturer. FDA

Do not approve a source based only on the name printed on a commercial quotation.

Assess the Material’s Role and Criticality

The level of assessment should reflect how the material is used and how a change could affect the product or process.

An active ingredient, a functional excipient and a processing aid may present different types of risk.

Questions to Consider:

• Is the material an active ingredient, excipient or processing aid?
• What function does it perform in the formulation or process?
• Does it affect a critical quality attribute?
• Are its properties linked to process performance?
• Could a variation affect product safety, quality or stability?
• Is the material used in more than one product?
• Is the material or source identified in regulatory documentation?
• Are there known supply-chain or contamination risks?

Use existing product knowledge, development information and manufacturing history to support the assessment.

Where knowledge is limited, identify the gap and determine whether additional information or studies are needed.

Compare Existing and Proposed Material Specifications

Review the proposed material against the approved specification and the needs of the manufacturing process.

Matching a material name or pharmacopoeial grade is a starting point, but it may not address every characteristic relevant to a specific product.

Comparison Areas May Include:

• Identification.
• Assay or content.
• Impurities and degradation-related substances.
• Particle size distribution.
• Moisture content.
• Physical form or polymorphic form, where relevant.
• Density and flow properties.
• Microbiological quality, where applicable.
• Residual solvents or other relevant contaminants.
• Storage conditions.
• Retest period or expiry date.
• Packaging and container suitability.

The relevant attributes depend on the material and its intended use.

If the proposed material has different characteristics, assess whether the existing specification and manufacturing process remain appropriate.

Qualify the Proposed Supplier

Supplier qualification should establish whether the proposed organisation can consistently supply material that meets the agreed requirements.

The qualification approach should reflect the material, the supplier’s role and the risks identified.

Qualification Activities May Include:

• Reviewing supplier questionnaires.
• Confirming the manufacturing site and supply chain.
• Assessing relevant licences and quality documentation.
• Reviewing manufacturing and quality systems.
• Evaluating certificates of analysis.
• Assessing material specifications and analytical methods.
• Reviewing quality history and available performance information.
• Conducting an audit or assessing suitable audit evidence, where justified.
• Agreeing on change notification and quality responsibilities.
• Documenting the approval decision.

An audit may be an important part of qualification for some suppliers. Its need, scope and timing should be determined under the applicable requirements and the organisation’s risk-based procedures.

Supplier approval should be documented by the appropriate quality function before routine procurement or use.

Review Supply-Chain Traceability

A material may pass through several organisations before reaching the pharmaceutical manufacturing site.

Understanding the supply chain helps identify where storage, transport, repackaging or other activities could affect material quality or traceability.

Traceability Checks Include:

• Actual material manufacturer and site.
• Approved distributors and agents.
• Batch identification through the supply chain.
• Storage conditions and locations.
• Transport conditions.
• Repackaging or relabelling activities.
• Controls to prevent mix-ups or contamination.
• Documentation accompanying each delivery.
• Procedures for investigating suspected issues.

Record the approved supply route where required by the quality system.

If the route changes after approval, assess whether the change requires a further review.

Assess Potential Effects on Manufacturing

A new material source may affect how a process behaves, even if incoming test results meet the approved specification.

For example, a change in excipient particle size or flow properties may influence powder handling or tablet compression.

Manufacturing Assessment Points Include:

• Dispensing and handling characteristics.
• Mixing and blending behaviour.
• Granulation performance, where applicable.
• Flow through manufacturing equipment.
• Compression or filling behaviour.
• Yield and process variability.
• In-process test results.
• Cleaning requirements.
• Equipment suitability.
• Potential effects on critical process parameters.

Use prior product knowledge to identify the characteristics most likely to influence the process.

Do not assume that identical processing instructions will necessarily produce identical results with every material source.

Plan Sampling and Analytical Assessment

The quality control team should determine how the proposed material will be sampled and tested before use.

The assessment may include standard incoming testing as well as additional comparative tests, depending on the identified risks.

Planning Questions Include:

• Which specification applies to the material?
• Which tests will be performed on receipt?
• Are additional tests needed for the change assessment?
• Are the analytical methods suitable for the proposed material?
• Are appropriate reference standards available?
• How will samples be collected and identified?
• How will unexpected or out-of-specification results be investigated?
• Who will review and approve the results?

A supplier’s certificate of analysis is useful supporting information, but its use should follow the manufacturer’s approved procedures and applicable requirements.

Consider Trial, Validation and Stability Activities

Depending on the material and product, a supplier change may require further evidence before implementation.

The team should assess whether laboratory comparisons, manufacturing trials, validation activities or stability studies are necessary.

Activities to Consider Include:

• Comparative testing of existing and proposed materials.
• Laboratory-scale formulation studies.
• Engineering or trial batches.
• Process performance assessment.
• Additional in-process monitoring.
• Finished product testing.
• Dissolution or other performance testing, where relevant.
• Stability studies or ongoing stability commitments.
• Cleaning or hold-time assessments, where relevant.

The type and extent of work should be justified by the risk assessment, product knowledge and applicable requirements.

A successful trial batch does not automatically replace required validation, regulatory approval or quality release.

Assess the Regulatory Impact

The regulatory team should review whether the proposed supplier change affects information submitted for the product or material.

Requirements can vary depending on the material, product, nature of the change and market where the medicine is supplied.

Regulatory Questions to Resolve:

• Is the current material manufacturer or manufacturing site identified in the dossier?
• Does the proposed change affect an approved specification or manufacturing process?
• Is a submission or notification required?
• Must regulatory approval be received before implementation?
• Is supporting quality, comparability or stability data needed?
• Are there commitments specific to the intended export market?
• Which products and registrations are affected?
• Who is responsible for preparing and submitting the change?

For products manufactured in India for export, assess the applicable Indian requirements and the requirements of each destination market.

A supplier’s commercial readiness does not establish that the change is ready for regulatory implementation.

Assign Responsibilities Across Manufacturing Partners

Supplier changes can involve the product owner, contract manufacturer, material manufacturer, distributor and other service providers.

Responsibilities should be clear before qualification work begins.

Functions to Involve Include:

• Procurement and supply chain.
• Quality assurance.
• Quality control.
• Manufacturing.
• Product development or technical services.
• Regulatory affairs.
• Validation specialists.
• Warehouse and logistics.
• Contract manufacturing partners.
• Product or marketing authorisation owners, where applicable.

Assign an owner for each assessment, supporting document and approval.

Where multiple organisations are involved, define how information will be shared and who has authority to approve the change.

Update Quality and Supply Agreements

A new supplier or changed supply arrangement may require a new agreement or an update to an existing one.

The agreement should clearly identify quality responsibilities and how changes or problems will be communicated.

Topics to Address Include:

• Material specification and agreed grade.
• Manufacturing and supply sites.
• Documentation supplied with each batch.
• Change notification requirements.
• Subcontracting or outsourced activities.
• Storage and transport conditions.
• Repackaging or relabelling responsibilities.
• Deviation and complaint handling.
• Investigation and corrective action.
• Audit arrangements, where applicable.
• Traceability and record retention.
• Communication of potential shortages or recalls.

The agreement should support the approved supplier qualification and change-control process.

A Practical Raw Material Supplier Change Checklist

Checklist area	What to confirm
Change description	Existing and proposed sources are clearly identified
Reason for change	Business, supply or quality reason is documented
Material criticality	Role and potential product impact are assessed
Manufacturer identity	Actual manufacturer and site are confirmed
Distributor details	Supply-chain parties and activities are identified
Specifications	Existing and proposed material requirements are compared
Supplier qualification	Required documents, assessments and approvals are completed
Traceability	Approved supply route and batch traceability are established
Quality risk assessment	Risks to product, process and supply are documented
Analytical assessment	Sampling, testing and method suitability are confirmed
Manufacturing impact	Potential effects on processing and in-process controls are reviewed
Additional studies	Trial, validation and stability needs are assessed
Regulatory impact	Required submissions, notifications and approvals are identified
Agreements	Quality and change-notification responsibilities are documented
Material receipt	Quarantine, testing and release arrangements are defined
Implementation	Quality and regulatory conditions are met before approved use
Monitoring	Initial batches and supplier performance are reviewed
Change closure	Results, open items and final approvals are documented

Hypothetical Example: Changing an Excipient Supplier

An Indian pharmaceutical manufacturer uses an excipient in a tablet formulation. The existing source experiences supply delays, so the manufacturer proposes a second supplier.

Both suppliers offer the same named excipient grade. However, the technical team identifies a potential difference in particle size distribution.

The Manufacturer’s Assessment May Include:

• Opening a change-control record.
• Confirming the proposed material manufacturer and site.
• Comparing specifications and available material data.
• Assessing the effect of particle size on blending and tablet compression.
• Qualifying the proposed supplier.
• Testing material samples according to an approved plan.
• Assessing the need for a manufacturing trial and stability work.
• Reviewing the regulatory impact for each affected market.
• Defining the conditions for quality approval and implementation.
• Monitoring the first batches manufactured with the new source.

The required activities depend on the formulation, available knowledge, risk assessment and applicable requirements.

Control the First Receipts and Initial Batches

After the change has received the required approvals, plan how the first deliveries and manufacturing batches will be controlled.

A supplier qualification decision should be supported by continued observation of actual material performance.

Controls May Include:

• Confirming the approved supplier and manufacturer on the purchase order.
• Checking the delivery against approved documentation.
• Verifying packaging, labels and batch identity.
• Placing received material in quarantine until release.
• Sampling and testing according to approved procedures.
• Recording the new material batch in manufacturing records.
• Monitoring relevant process and product results.
• Investigating unusual trends or deviations.
• Confirming who can authorise material and product release.

Do not release incoming material for use until the required receipt, testing and quality checks have been completed.

Monitor Supplier Performance After Approval

Supplier qualification is not necessarily a one-time activity.

Ongoing monitoring helps the manufacturer identify changes in material quality, documentation or delivery performance.

Performance Measures May Include:

• Incoming material test results.
• Rejected or returned deliveries.
• Deviations and complaints.
• Changes in impurity or physical-property trends.
• Completeness of certificates and shipment documents.
• Delivery reliability.
• Response time to investigations.
• Timely notification of proposed changes.
• Audit or reassessment outcomes.

Review the results at intervals defined by the quality system and the level of risk.

If performance changes, determine whether additional controls, investigation or requalification are needed.

Document Deviations and Close the Change

Record any unexpected result or departure from the approved change plan.

The quality team should assess whether the issue affects material suitability, product quality, regulatory commitments or the planned implementation.

The Closure Review Should Confirm:

• Planned qualification activities are complete.
• Results have been reviewed against approved criteria.
• Deviations and investigations have been addressed.
• Required regulatory actions are complete or appropriately controlled.
• Relevant documents and systems have been updated.
• Staff have received necessary training.
• Supplier and material approval status is clear.
• Any remaining actions have assigned owners and deadlines.
• The final change decision is approved and recorded.

Do not close the change simply because the first shipment has arrived.

ICH Q10 recommends evaluating a change after implementation to confirm that it achieved its objectives without an adverse effect on product quality. database.ich.org

Common Supplier Change Mistakes to Avoid

Treating the Material Name as Proof of Equivalence

Compare the characteristics that matter to the specific formulation and manufacturing process.

Approving a Distributor Without Identifying the Manufacturer

Confirm the actual source, manufacturing site and supply route.

Leaving Regulatory Assessment Until After Procurement

Review dossier and destination-market requirements before committing to implementation.

Assuming a Certificate of Analysis Completes Qualification

Assess the supplier, material, supply chain and supporting quality information under the approved procedure.

Using Trial Batch Results as Automatic Approval

Review trial outcomes alongside the required quality, validation and regulatory evidence.

Introducing the Material Before Updating Controlled Documents

Update the approved supplier list, specifications and other affected instructions before the authorised change takes effect.

Failing to Monitor Initial Performance

Review early deliveries and manufacturing results to confirm that the change performs as expected.

Coordinating Supplier Changes With Zircon Medtech

Businesses discussing pharmaceutical manufacturing or supply arrangements with Zircon Medtech should identify the organisations responsible for material sourcing, supplier qualification and change approval.

The required activities depend on the product, manufacturer, material and intended market.

Request Written Confirmation of:

• Product and material details.
• Existing and proposed material sources.
• Actual manufacturer and manufacturing site.
• Responsibility for supplier qualification.
• Applicable material specifications.
• Sampling and testing responsibilities.
• Planned comparative, trial or stability work.
• Regulatory assessment and submission responsibilities.
• Quality agreement and change-notification arrangements.
• Conditions for material and batch release.
• Implementation milestones and ongoing monitoring.

Confirm the proposed responsibilities for the specific project rather than assuming one organisation performs every activity.

Turning a Supplier Change Into a Controlled Implementation

Pharmaceutical manufacturing in India benefits from a supplier change process that connects procurement decisions with quality, technical and regulatory review.

Identify the proposed source, assess the material and supplier, and establish the evidence needed before implementation. Complete the required approvals, control the first receipts and monitor performance after the change.

A documented approach helps manufacturing partners maintain oversight of raw material quality while supporting a reliable supply chain.